This trial is active, not recruiting.

Condition delusion of reference
Treatments endocrine society upper limit dosage vitamin d, institute of medicine (iom) dosage vitamin d, calcium
Sponsor Winthrop University Hospital
Start date September 2013
End date July 2016
Trial size 132 participants
Trial identifier NCT02019381, 13005


Recently two distinguished committees, Institute of Medicine (IOM) and The Endocrine Society have proposed different intake guidelines for Calcium and Vitamin D. We wish to compare the effects of both of them on calcium metabolism and bone turnover. We propose a one year randomized double blinded study for the same.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose health services research
Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
endocrine society upper limit dosage vitamin d
Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
institute of medicine (iom) dosage vitamin d
IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium

Primary Outcomes

Compare the effects of 10000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on incidence of hypercalciuria (spot urine calcium:creatinine ratio, 24-hour urine calcium).
time frame: One year

Secondary Outcomes

Compare the effects of 10,000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on vitamin D metabolism [25(OH)D, 1,25(OH)2D], and bone turnover.
time frame: One year

Eligibility Criteria

Female participants from 50 years up to 90 years old.

Inclusion Criteria: 1. Healthy White women aged 50 and older who have been postmenopausal for at least 2 year (i.e. absence of menstrual period for a period of 24 months or more). 2. Willingness to discontinue self-administration of vitamin D and calcium supplements. Participants must be at least three months off supplements before starting the study. 3. Willingness to take study medications and participate in study for one year. 4. Written informed Consent Signed. 5. Patients with hypertension and diabetes stable for last three months. Exclusion Criteria: 1. History of hypercalciuria (24-hour urinary calcium excretion >250 mg), hypercalcemia (serum calcium >10.6), nephrolithiasis and active sarcoidosis will be excluded. 2. Serum 25-hydroxyvitamin D level >80 nmol/L or history of primary hyperparathyroidism. 3. Dietary calcium intake of >2000mg/day will be excluded 4. Use of medication that influences bone or vitamin D metabolism (e.g. anticonvulsant medications, glucocorticoids, Highly Active AntiRetroviral Therapy [AIDS treatment], antirejection medications, chronic use of steroids, high dose diuretics) 5. Treatment with Hormone replacement therapy, Selective Estrogen Receptor Modulators, Calcitonin, Parathyroid hormone , androgens, bisphosphonates, phosphate or anabolic steroids 6 months prior to the study. 6. Use of systemic steroids (oral or intravenous) within the last year at an average dose of more than 5mg/day of oral prednisone or an equivalent for a period of three months or more prior to screening. 7. Chronic medical illness including Chronic liver disease, uncontrolled diabetes mellitus; recent history of myocardial infarction or heart failure; newly diagnosed or active malignancy; uncontrolled hypertension; obesity (BMI>35 kg/m2); malabsorption, anemia, leukemia, or other hematologic abnormalities; lupus, rheumatoid arthritis, sarcoidosis, or other rheumatologic disease; chronic kidney disease, metabolic bone disease. 8. Unexplained weight loss of >15% during the previous year or history of anorexia nervosa 9. > 1 pack per day tobacco use or > 2 alcoholic beverages per day 10. Unwillingness to forego self-administration of vitamin D and calcium-containing supplements. 11. Participation in another investigational trial in the past 30 days prior to the screening evaluation 12. Significant deviation from normal in medical history, physical examination, or laboratory tests as evaluated by the primary investigator. 13. Patients with unstable hypertension or diabetes.

Additional Information

Official title The Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism in Postmenopausal White Women.
Principal investigator John Aloia, MD
Description The specific aims of this study proposal are to determine the following: 1. To compare the two different intake guidelines for Calcium and Vitamin D Supplementation at its recommended tolerable upper limit on serum and urinary calcium in white postmenopausal Women. 2. Compare the effects above mentioned two intake guidelines on Vitamin D metabolism [25(OH)D, 1,25(OH)2D] and bone turnover. Participants will be randomly assigned to Group A or Group B based on different dosages of study medications. Group A: 10,000 IU (International Units)Vitamin D + Placebo (sugar pill) 600IU Vitamin D + Two pills Calcium containing 600mg calcium each. Group B: 600 IU Vitamin D + Placebo (sugar pill) 10,000 IU Vitamin D + Two pills Calcium containing 600mg calcium each. In addition to the calcium supplements, they will guide to include approximately 800mg of calcium in their daily diet. At visit 2, fasting blood and spot urine will be collected. A urinal will be dispensed for collection of 24-hour urine for urinary calcium to be brought in next day. Study medication will be dispensed and participants will be asked not to discard unused medications and to bring all study medications next study visit. Visit 3, 4, 5, 6 will essentially be the same as visit 2, with subjects returning unused study medication and given new tablets each visit. Except on visit 6 no further study medications will be dispensed, after collecting the previous supply. Food frequency questionnaires will be filled out at the initial visit and final visit. Diet will be assessed using 3-day diet history form and Nutrition Pro analysis software. Patients will be asked to refrain from taking other Vitamin D supplements and to continue their usual calcium intake.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Winthrop University Hospital.